Clinical Trials
714 trialsCaDAnCe-101
BeOne Medicines
A Phase Ib/II Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD.
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing
National Institutes of Health Clinical Center (CC)
Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype
Roswell Park Cancer Institute
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
Fred Hutchinson Cancer Center
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
A Rollover Study of CC-122
Bristol-Myers Squibb
CAN3001
Janssen Research & Development, LLC
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
Pfizer
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
Cedars-Sinai Medical Center
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
EPCORE™ NHL-3
Genmab
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
AbbVie
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Incyte Corporation
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
Bio-CAR-T BS Study
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
DALY 2-EU
Miltenyi Biomedicine GmbH
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
Study of Out of Specification for Tisagenlecleucel
Novartis
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
Novartis
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Mayo Clinic
OPAL
AVM Biotechnology Inc
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T
Calibr, a division of Scripps Research
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
QUADvance
AvenCell Therapeutics, Inc.
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Vironexis Biotherapeutics Inc.
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Nurix Therapeutics, Inc.
CLOVER-WaM
Cellectar Biosciences, Inc.
A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML
MEI Pharma, Inc.
Atalanta-1
Lakefront Biotherapeutics NV
A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies
BeOne Medicines
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
University of Chicago
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Fred Hutchinson Cancer Center
RELATIVITY-069
Bristol-Myers Squibb
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Medical College of Wisconsin
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
BeOne Medicines
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ascentage Pharma Group Inc.
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Children's Hospital Medical Center, Cincinnati
PRODIGY
University of Utah
ACITAC-001
Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Newave Pharmaceutical Inc
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Emory University
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)
Eli Lilly and Company